@entity1344 as a prognostic marker in XXXX .

@entity5 @entity1 @entity3 @entity1344
BACKGROUND: @entity5 is the third most common @entity5 in @entity1 globally, and despite treatment, distant @entity3 and nodal recurrence will still develop in approximately 30% of @entity1 . The ability to predict which @entity1 are likely to experience distant relapse would allow clinicians to better tailor treatment. Previous studies have investigated the role of @entity1344 ( @entity1344 ) in @entity5 , which can promote @entity5 initiation and growth; a hallmark of @entity1 @entity5 . In this study, we sought to examine the published CIN70 gene signature in a cohort of @entity5 @entity1 treated at the Princess Margaret (PM) Cancer Centre and an independent cohort of The @entity5 (TCGA) @entity5 @entity1 , to determine if this @entity1344 signature associated with @entity1 outcome. METHODS: @entity5 samples were collected from 79 @entity1 , treated between 2000-2007 at the PM, prior to undergoing curative chemo-radiation. Total RNA was extracted from each @entity1 sample and analyzed using the GeneChip @entity1 Genome U133 Plus 2.0 array (Affymetrix). RESULTS: High CIN70 scores were significantly related to increased chromosomal alterations in TCGA @entity5 @entity1 , including a higher percentage of genome altered and a higher number of copy number alterations. In addition, this same CIN70 signature was shown to be predictive of para-aortic nodal relapse in the PM Cancer Centre cohort. CONCLUSIONS: These findings demonstrate that @entity1344 plays an important role in @entity5 , and is significantly associated with @entity1 outcome. For the first time, this CIN70 gene signature provided prognostic value for @entity1 with @entity5 .
